Generation of efficient human blood progenitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells

被引:18
作者
Sellner, Leopold [1 ]
Stiefelhagen, Marius [1 ]
Kleinschmidt, Juergen A.
Laufs, Stephanie [2 ,3 ]
Wenz, Frederik [4 ]
Fruehauf, Stefan [5 ]
Zeller, W. Jens [1 ]
Veldwijk, Marlon R. [1 ,4 ]
机构
[1] German Canc Res Ctr Heidelberg, Pharmacol Canc Treatment G402, D-69120 Heidelberg, Germany
[2] German Canc Res Ctr, Mol Oncol Solid Tumors G360, D-6900 Heidelberg, Germany
[3] Med Mannheim Ctr, Dept Expt Surg, Mannheim, Germany
[4] Univ Heidelberg, Mannheim Med Ctr, Dept Radiat Oncol, D-6800 Mannheim, Germany
[5] Paracelsus Klin, Ctr Tumor Diagnost & Therapy, Osnabruck, Germany
关键词
D O I
10.1016/j.exphem.2008.03.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Currently standard recombinant adeno-associated virus serotype 2(rAAV2)-based vectors lack the efficiency for gene transfer into primary human CD34(+) peripheral blood progenitor cells (PBPC). Materials and Methods. An advancement in vector development now allows the generation of rAAV capsid mutants that offer higher target cell efficiency and specificity. To increase the gene transfer into hematopoietic progenitor cells, we applied this method for the first time on primary human CD34(+) PBPC cells. Results. On a panel of leukemia cell lines (CML/AML), significantly higher gene transfer efficiency of the rAAV capsid mutants (up to 100% gene transfer) was observed compared to standard rAAV2 vectors. A higher transduction efficiency in the imatinib-resistant cell line LAMA84-R than in their sensitive counterpart LAMA84-S and a pronounced difference in susceptibility for the capsid mutants vs rAAV2 in LAMA84-S were particularly striking. On solid tumor cell lines, on the other hand, rAAV2 was more efficient than the capsid mutants, suggesting an increased specificity of our capsid mutants for hematopoietic progenitor cells. On primary human CD34(+) PBPC significantly higher (up to eightfold; 16% green fluorescent protein-positive) gene transfer could be obtained with the newly generated vectors compared to standard rAAV2 vectors. Conclusion. These novel vectors may enable efficient gene transfer using rAAV-based vectors into primary human blood progenitor cells for a future clinical application. (c) 2008 ISEH Society for Hematology and Stem Cells. Published by Elsevier Inc.
引用
收藏
页码:957 / 964
页数:8
相关论文
共 58 条
[1]   A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease [J].
Aitken, ML ;
Moss, RB ;
Waltz, DA ;
Dovey, ME ;
Tonelli, MR ;
McNamara, SC ;
Gibson, RL ;
Ramsey, BW ;
Carter, BJ ;
Reynolds, TC .
HUMAN GENE THERAPY, 2001, 12 (15) :1907-1916
[2]   Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning [J].
Aiuti, A ;
Slavin, S ;
Aker, M ;
Ficara, F ;
Deola, S ;
Mortellaro, A ;
Morecki, S ;
Andolfi, G ;
Tabucchi, A ;
Carlucci, F ;
Marinello, E ;
Cattaneo, F ;
Vai, S ;
Servida, P ;
Miniero, R ;
Roncarolo, MG ;
Bordignon, C .
SCIENCE, 2002, 296 (5577) :2410-2413
[3]   Transfer of contaminants in adeno-associated virus vector stocks can mimic transduction and lead to artifactual results [J].
Alexander, IE ;
Russell, DW ;
Miller, AD .
HUMAN GENE THERAPY, 1997, 8 (16) :1911-1920
[4]   DNA-DAMAGING AGENTS GREATLY INCREASE THE TRANSDUCTION OF NONDIVIDING CELLS BY ADENOASSOCIATED VIRUS VECTORS [J].
ALEXANDER, IE ;
RUSSELL, DW ;
MILLER, AD .
JOURNAL OF VIROLOGY, 1994, 68 (12) :8282-8287
[5]   A phase I/II clinical trial of β-globin gene therapy for β-thalassemia. [J].
Bank, A ;
Dorazio, R ;
Leboulch, P .
COOLEY'S ANEMIA EIGHTH SYMPOSIUM, 2005, 1054 :308-316
[6]   Susceptibility of mesothelioma cell lines to adeno-associated virus 2 vector-based suicide gene therapy [J].
Berlinghoff, S ;
Veldwijk, MR ;
Laufs, S ;
Maser, HP ;
Jauch, A ;
Wenz, F ;
Zeller, WJ ;
Fruehauf, S .
LUNG CANCER, 2004, 46 (02) :179-186
[7]   SEROEPIDEMIOLOGIC STUDY OF ADENOVIRUS-ASSOCIATED VIRUS INFECTION IN INFANTS AND CHILDREN [J].
BLACKLOW, NR ;
HOGGAN, MD ;
SERENO, MS ;
BRANDT, CD ;
KIM, HW ;
PARROTT, RH ;
CHANOCK, RM .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1971, 94 (04) :359-&
[8]   Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease [J].
Cavazzana-Calvo, M ;
Hacein-Bey, S ;
Basile, CD ;
Gross, F ;
Yvon, E ;
Nusbaum, P ;
Selz, F ;
Hue, C ;
Certain, S ;
Casanova, JL ;
Bousso, P ;
Le Deist, F ;
Fischer, A .
SCIENCE, 2000, 288 (5466) :669-672
[9]   Transduction of primitive human marrow and cord blood-derived hematopoietic progenitor cells with adeno-associated virus vectors [J].
Chatterjee, S ;
Li, W ;
Wong, CA ;
Fisher-Adams, G ;
Lu, D ;
Guha, M ;
Macer, JA ;
Forman, SJ ;
Wong, KK .
BLOOD, 1999, 93 (06) :1882-1894
[10]  
Conrad CK, 1996, GENE THER, V3, P658